{
  "ticker": "ALMS",
  "company_name": "Alumis Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05953688",
      "title": "POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis",
      "start_date": "2023-06-14",
      "completion_date": "2024-08-13",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT05431634",
      "title": "Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Safety and Tolerability",
      "start_date": "2022-05-12",
      "completion_date": "2022-12-31",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT05330858",
      "title": "Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Pharmacokinetics",
      "start_date": "2022-03-17",
      "completion_date": "2022-09-20",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT06962774",
      "title": "An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Renal Impairment",
      "start_date": "2025-04-23",
      "completion_date": "2025-08-01",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT05739435",
      "title": "Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Plaque Psoriasis",
      "start_date": "2023-01-17",
      "completion_date": "2026-12-30",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT06952634",
      "title": "An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Hepatic Impairment",
      "start_date": "2025-04-29",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT05600036",
      "title": "A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Plaque Psoriasis",
      "start_date": "2022-09-27",
      "completion_date": "2023-07-25",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT06588738",
      "title": "A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Plaque Psoriasis",
      "start_date": "2024-08-20",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT05966480",
      "title": "Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "SLE",
      "start_date": "2023-06-26",
      "completion_date": "2027-09-01",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    },
    {
      "nct_id": "NCT06846541",
      "title": "Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis",
      "start_date": "2025-01-08",
      "completion_date": "2028-11",
      "enrollment": 0,
      "sponsor": "Alumis Inc"
    }
  ],
  "summary": {
    "total_trials": 11,
    "by_phase": {
      "PHASE2": 4,
      "PHASE1": 4,
      "PHASE3": 3
    },
    "by_status": {
      "TERMINATED": 1,
      "COMPLETED": 4,
      "ACTIVE_NOT_RECRUITING": 4,
      "RECRUITING": 2
    },
    "active_trials": 6,
    "completed_trials": 4,
    "conditions": [
      "Hepatic Impairment",
      "Pharmacokinetics",
      "Plaque Psoriasis",
      "Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis",
      "Renal Impairment",
      "SLE",
      "Safety and Tolerability",
      "Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:12.096041",
    "search_query": "Alumis Inc.",
    "url": "https://clinicaltrials.gov/search?term=Alumis+Inc."
  }
}